Brief Summary
The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas.
Intervention / Treatment
- Drug: TLN-121
- Drug: TLN-254
- Drug: TLN-121
Inclusion Criteria:
Disease Characteristics
- Participant must have measurable disease at study entry
- Participants must have one of the following histologically documented hematologic malignancies:
- Diffuse large B-cell lymphomacancers of the lymphatic system (DLBCL), not otherwise specified (DLBCL, NOS), Follicular lymphoma (FL) gradea description of how abnormal cancer cells and tissue look under a microscope when compared to healthy cells 3b, or transformed lymphoma from FL following at least 2 prior lines of therapy.
- FL grade 1-3a that requires treatment following at least 2 prior lines of therapy.
- The following Peripheral T-cell lymphoma (PTCL) subtypes that have relapsed after, or not responded to at least 1 prior systemic treatment regimen:
- Nodal T-follicular helper (Tfh) cell lymphoma angioimmunoblastic; Follicular helper T-cell lymphoma, angioimmunoblastic type (AITL).
- Nodal Tfh cell lymphoma, follicular type; Follicular helper T-cell lymphoma, follicular type.
- Nodal Tfh cell lymphoma, NOS; Follicular helper T-cell lymphoma, NOS.
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status of 0 or 1.